"XING
Group Holdings, a
Brisbane-based private Australian medical technology company, is actively
seeking joint venture (JV) partners for a spin-off of its diagnostics division
to facilitate product commercialization, starting with its COVID-19 test kit,
said CEO Tom Esplin.
The company’s corporate advisor is BlueMount
Capital (Queensland), but it welcomes approaches from other
advisors with potential JV partners that can assist with manufacturing
processes and have distribution capability, Esplin said.
XING Group plans to spin off its diagnostics division into a separate entity,
in which it intends to maintain a majority stake with the rest owned by the JV
partner, he said. It is already having partnership and investment conversations
with diagnostics and life sciences companies in the US and Europe and is also
willing to hear from significant players in other markets like China, Japan and
South Korea, Esplin said."
Please download the full announcement via the link below.
For more information about XING / Project Curatio, please click here.
